

Building Smarter Drug Development

with the Patient at the Center

Patient Engagement


Drug development often misses the mark because it overlooks the most important voice: the patient's. Timelines stretch. Trials stall. Treatments fail to deliver. At Wemedoo, we fix that.

We bring patients into the development process using structured tools and clean data pipelines. Our approach helps research teams focus on real needs, improve study design, streamline recruitment, and strengthen regulatory and market outcomes.



Tools & Methods

Wemedoo delivers modular tools and expert services that support patient-centered R&D:



Data value chain in biopharmaceutical industry

Research & Discovery

We help define unmet clinical needs by engaging directly with patients and caregivers. Our tools uncover insights into disease burden and support the identification of promising therapeutic targets early in the development cycle.

Preclinical Development

We capture patient preferences regarding drug delivery methods to inform the study design. This helps evaluate the likely impact on adherence and define meaningful endpoints that matter to the people who will use the drug.



Clinical Development

Our approach supports patient-centered trial design. We work to define patient-driven endpoints, diversify recruitment populations, and identify the most suitable regions and trial sites using real-world input and regional analytics.

Regulatory Approval

We facilitate patient involvement throughout the regulatory process. This includes preparing patient testimonies for hearings, gathering preference data, organizing patient-focused development meetings, and involving patient representatives on advisory committees.

Marketing & Sales

We help integrate patient experience into communication strategies. This includes real stories and testimonials, pricing models that reflect patient affordability concerns, and educational materials developed with patient understanding in mind.

Post-Marketing Activities

We continue gathering patient feedback after launch. Testimonials, affordability concerns, and lived experiences help refine messaging, support ongoing education, and improve long-term treatment adherence and access.

Wemedoo is scaling. Our roadmap includes:




Expanded trial site targeting using social network data

Longitudinal insights via connected patient registries


Advanced analytics for submission-ready visualizations

Wemedoo directly addresses inefficiencies in the pharmaceutical value chain, from trial failure to slow approvals to weak uptake.




We have built the infrastructure. We have the expertise. We are aligned with where the industry is going: faster, smarter, patient-first development.

Technical Framework for Patient Data Flow and Decision Support



We bring deep expertise and smart technology to unlock the full potential of clinical data, advancing patient-first, efficient research. We seamlessly connect people, processes, and data to drive real impact across the clinical landscape.

Modular Architecture Overview: Connected Health Modules



Science Behind:

- Title and abstract screening for literature reviews using large language models: an exploratory study in the biomedical domain*, Fabio Dennstädt, Nikola Cihoric et. al. Systematic reviews, Volume 13, Issue 1, Pages 158, BioMed central
- Decision making criteria in oncology*, Markus Glatzer, Paul Martin Putora et. al. Oncology, Volume 98, Issue 6 , Pages 370-378
- Creation of a CDE-based data structure for radiotherapeutic decision-making in breast cancer*, Fabio Dennstädt, Nikola Cihoric et. al. Volume 155, Pages 82-83
- Application of a general LLM-based classification system to retrieve information about oncological trials*, Fabio Dennstädt, Janna Hastings et. al. medRxiv, Pages: 2024.12. 03.24318390